XNAS:DARA Insider Activity 4 Filing - 5/15/2012

Effective Date 5/15/2012

XNAS:DARA (): Fair Value Estimate
Premium
XNAS:DARA (): Consider Buying
Premium
XNAS:DARA (): Consider Selling
Premium
XNAS:DARA (): Fair Value Uncertainty
Premium
XNAS:DARA (): Economic Moat
Premium
XNAS:DARA (): Stewardship
Premium
 
FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
CLEMENT CHRISTOPHER G
  2. Issuer Name and Ticker or Trading Symbol
DARA BioSciences, Inc. [DARA]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
President and COO
(Last)
(First)
(Middle)
C/O DARA BIOSCIENCES, 8601 SIX FORKS ROAD, SUITE 160
3. Date of Earliest Transaction (Month/Day/Year)
05/15/2012
(Street)

RALEIGH, NC 27615
4. If Amendment, Date Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)
7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 05/15/2012   A(1)   43,133 A (2) 258,794 D  

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)
6. Date Exercisable and Expiration Date
(Month/Day/Year)
7. Title and Amount of Underlying Securities
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)
11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Reporting Owners

Reporting Owner Name / Address Relationships
 Director  10% Owner  Officer  Other
CLEMENT CHRISTOPHER G
C/O DARA BIOSCIENCES
8601 SIX FORKS ROAD, SUITE 160
RALEIGH, NC 27615
  X     President and COO  

Signatures

 /s/ Chris Clement by Mark R. Busch, attorney-in-fact   05/30/2012
** Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) On May 15, 2012, the reporting person became entitled to receive shares of DARA BioSciences, Inc. ("DARA") common stock pursuant to an "earn-out" provision in the merger agreement pursuant to which DARA acquired all of the outstanding common stock of Oncogenerix, Inc. on January 17, 2012 (the "Merger"). The merger agreement provided that the shareholders of Oncogenerix would receive additional shares of DARA common stock, for no additional consideration, if DARA achieves certain milestones during the 60 months following the effective date of the merger, as a result of which Oncogenerix's former shareholders, including the reporting person, acquired additional shares of DARA common stock pursuant to the merger agreement. The reporting person's right to receive additional shares became fixed and irrevocable on January 17, 2012, the effective date of the Merger.
(2) The number of shares issuable pursuant to the earn-out right was determined, pursuant to the merger agreement, based on a DARA common stock price of $1.55 per share, which was the closing price of DARA common stock on the effective date of the Merger.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

XNAS:DARA DARA Biosciences Inc Insider Activity 4 Filling

DARA Biosciences Inc XNAS:DARA Stock - Get Insider Activity SEC Filing of DARA Biosciences Inc XNAS:DARA stocks, including company profile, shares outstanding, strategy, business segments, operations, officers, consolidated financial statements, financial notes and ownership information.

Content Partners
XNAS:DARA Insider Activity 4 Filing - 5/15/2012
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Title |  Date |  Company |  Symbol |  Interest |  Popularity

Previous: XNAS:DARA Insider Activity 4 Filing - 5/15/2012  |  Next: XNAS:DARA Insider Activity 4 Filing - 5/29/2012